NATCOPHARM Natco Pharma shares are trading around ₹975 today (7 July 2026)
Natco Pharma shares are trading around ₹975 today (7 July 2026), up nearly 4.7% after posting Q4 FY26 results that showed weaker profits but moderate recovery in recent sessions. The company also announced a management change with the superannuation of its VP – Operations, and recently received USFDA approval (with Lupin) for Eribulin Mesylate Injection. 📊 Natco Pharma Share Price Snapshot – 7 July 2026 BSE Price: ₹975 (+4.65%) NSE Price: ₹968 (+3.88%) Day’s Range: ₹924.65 – ₹976.90 52-Week Range: ₹789.30 – ₹1,226.10 Volume: ~8.9 lakh shares traded on NSE 🔹 Q4 FY26 Results Highlights Revenue & Profit: Net profit fell 34% YoY, with weak operating margins. EBITDA: Declined sharply, reflecting cost pressures. Tax Benefit: One-time tax-related gain partially cushioned earnings. Investor Sentiment: Shares had crashed ~15% post-results in May but are now showing recovery momentum. 🔹 Corporate Announcements Management Change: Mr. N. Malleswara Rao (VP – Operations, Pharma Division, Kothur) retired on 30 June 2026. USFDA Approval: Natco Pharma and Lupin received approval for Eribulin Mesylate Injection, strengthening oncology portfolio. Trading Window: Closed as per SEBI guidelines for Q4 results. 📈 Technical & Market Outlook Long-Term Trend: Bearish (last 6 months). Short-Term Trend: Moderately bullish (last 1–2 weeks). Support Levels: ₹920–930 zone. Resistance Levels: ₹980–1,000 zone. Analyst View: Near-term recovery possible, but sustained upside depends on margin improvement and USFDA-driven product launches. ⚠️ Risks & Challenges Profit Volatility: Earnings remain under pressure despite revenue growth. Global Competition: Oncology generics face pricing pressure in US markets. Regulatory Dependence: USFDA approvals critical for growth; delays can impact performance. Investor Sentiment: Stock still down significantly from 52-week high of ₹1,226.
